Vimarsana
Biggest News Aggregation in the World

Page 38 - Planegg News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Planegg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Planegg Today - Breaking & Trending Today

MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution -November 27, 2023 at 10:01 am EST - Vimarsana News

MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution -November 27, 2023 at 10:01 am EST

EQS Voting Rights Announcement: MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of...

MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution -November 23, 2023 at 10:01 am EST - Vimarsana News

MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution -November 23, 2023 at 10:01 am EST

EQS Voting Rights Announcement: MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of...

Ad hoc: MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction - Vimarsana News

Ad hoc: MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction

20.11.2023 - Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014MANIFEST-2 met primary endpoint, nearly doubling SVR35 response rate (66% versus 35%)The key secondary endpoints assessing symptom reduction, ... Seite 1

MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction - Vimarsana News

MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction

EQS-News: MorphoSys AG / Key word(s): Study resultsMorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction 20.11.2023 / 22:29 CET/CESTThe issuer is solely responsible for the content of this a...

Dpa-AFX Overview: COMPANIES from 21.11.2023 - 15 -November 21, 2023 at 09:21 am EST - Vimarsana News

Dpa-AFX Overview: COMPANIES from 21.11.2023 - 15 -November 21, 2023 at 09:21 am EST

ROUNDUP: Rheinmetall expects even more business thanks to armaments boom - share price record DÜSSELDORF/UNTERLÜSS - In view of the war in Europe and rising defense budgets in Western...